Abstract

Magnetic resonance imaging (MRI) has unveiled specific AD alterations at different stages of the AD pathophysiologic continuum that constitutes what has been established as the ‘AD signature’. To what extent MRI can detect amyloid-related cerebral changes from structural MRI in unimpaired individuals is still an area open for exploration.